N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 14.5 CNY 2.98% Market Closed
Market Cap: 23.4B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 25.68 CNY. Compared to the current market price of 14.5 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
25.68 CNY
Undervaluation 44%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

6
P/S
P/S
Price to Sales
6
vs History
72
vs Industry
23
Median 3Y
6.1
Median 5Y
7.3
Industry
2.4
Forward
5.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
23
Median 3Y
19.8
Median 5Y
25.4
Industry
20.8
Forward
25.6
More Details
15.6
P/OCF
P/OCF
Price to OCF
15.6
vs History
48
vs Industry
28
Median 3Y
25.1
Median 5Y
14.9
Industry
15.4
More Details
9.6
P/FCFE
P/FCFE
Price to FCFE
9.6
vs History
50
vs Industry
30
Median 3Y
9.7
Median 5Y
9.6
Industry
22.8
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
72
vs Industry
20
Median 3Y
3.8
Median 5Y
4.9
Industry
2
More Details
6.1
EV/S
EV/S
Enterprise Value to Sales
6.1
vs History
74
vs Industry
22
Median 3Y
6.2
Median 5Y
7.9
Industry
2.5
Forward
5.5
More Details
15
EV/GP
EV/GP
Enterprise Value to Gross Profit
15
vs History
56
vs Industry
14
Median 3Y
14.5
Median 5Y
15.1
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
19
Median 3Y
22.1
Median 5Y
25.3
Industry
12.7
Forward
18.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
23
Median 3Y
22.1
Median 5Y
25.3
Industry
15.8
Forward
24.4
More Details
15.8
EV/OCF
EV/OCF
Enterprise Value to OCF
15.8
vs History
48
vs Industry
27
Median 3Y
26.3
Median 5Y
15.3
Industry
14
More Details
27.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
27.9
vs History
40
vs Industry
18
Median 3Y
47.5
Median 5Y
20.6
Industry
18.3
More Details
3.4
EV/IC
EV/IC
Enterprise Value to IC
3.4
vs History
64
vs Industry
23
Median 3Y
3.3
Median 5Y
3.8
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
23.4B CNY 6 -55.4 -60.6 -60.6
US
Eli Lilly and Co
NYSE:LLY
757B USD 16.8 71.5 41.6 45.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.9B USD 4.2 26.2 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.3 21.1 13.9 15.8
CH
Roche Holding AG
SIX:ROG
233.1B CHF 4 20.3 11.3 13.4
UK
AstraZeneca PLC
LSE:AZN
176.2B GBP 4.2 32.4 126.9 193.7
CH
Novartis AG
SIX:NOVN
199.3B CHF 4.4 18.9 11.4 14.6
US
Merck & Co Inc
NYSE:MRK
220.6B USD 3.4 12.9 8.7 10.3
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
139.2B USD 2.2 17.3 8.4 11.9
P/E Multiple
Earnings Growth PEG
CN
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Average P/E: 27.6
Negative Multiple: -55.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
71.5
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.2
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
21.1
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.3
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.4
36%
0.9
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
US
Merck & Co Inc
NYSE:MRK
12.9
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Average EV/EBITDA: 434.8
Negative Multiple: -60.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.6
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Average EV/EBIT: 1 869.5
Negative Multiple: -60.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.9
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.7
21%
9.2
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.9
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.